Lineage Starts Manufacturing Work Before Huntington’s Deal — Its Cash Runway Moves Forward One Quarter

Existing supplies cover the planned 21-patient trial, but Lineage still must test its new cell bank and compare production processes.

Share
Lineage Starts Manufacturing Work Before Huntington’s Deal — Its Cash Runway Moves Forward One Quarter

Lineage Cell Therapeutics, which develops therapies to replace damaged or lost cells, began manufacturing work before completing its purchase of Huntington’s developer NeuroAirmid Therapeutics, Chief Executive Officer Brian Culley said on Thursday’s earnings call. The deal’s approximately $4.3 million in initial external cash payments brought its expected cash runway forward one quarter, to the second quarter of 2028.

A Cell Bank, Not Finished Scale-Up

Culley told a B. Riley analyst that Lineage had filled a master cell bank — the starting stock for future production — that morning in California. The company began that work at its own risk before buying NeuroAirmid and its clinical-stage Huntington’s program, HUNT1.

Existing material made using NeuroAirmid’s original process is sufficient for the planned 21-patient trial. The new bank still needs release and analytical testing, and Lineage is developing a production method intended to work at industrial scale.

An H.C. Wainwright analyst pressed Culley on the bottlenecks in moving from academic production to commercial manufacturing. He cautioned that “the rate limiting work is very difficult to project” because experience cannot identify every hurdle in advance.

Lineage already owned commercial development rights to the cell line used for HUNT1. Culley said those rights helped in negotiations, while the company’s use of the same line in other development work gave it a technical starting point.

Lineage will take responsibility for future manufacturing, process development and scale-up. It will also take over clinical development after the current University of California, Irvine study finishes; moving to its production process will require testing to establish that the cell products are comparable.

Six Patients, Safety Comes First

HUNT1 adds a Huntington’s program alongside Lineage’s clinical-stage OpRegen therapy for vision loss associated with dry age-related macular degeneration and OPC1 for spinal cord injury. Roche and Genentech are developing OpRegen under a worldwide agreement; Lineage also has the preclinical hearing-loss program ReSonance.

Dr. Priyantha Herath, Lineage’s senior vice president and head of clinical, said Huntington’s destroys neurons involved in movement, cognition and behavior. The company hopes HUNT1 can replace lost cells and support surviving neurons, an approach distinct from treatments aimed at reducing the mutant Huntington protein.

The early-stage trial gives patients a single injection into the striatum, a brain region affected early in the disease, under real-time MRI guidance. It enrolls adults aged 18 to 65 with genetically confirmed, early symptomatic Huntington’s.

Six patients have been dosed, with no serious adverse events reported to date. Safety is the main goal: independent monitoring gates each dose increase, while functional assessments, imaging and biomarkers explore possible treatment activity.

The dose-escalation portion tests 2 million to 16 million cells in four groups of three patients. A planned expansion adds nine patients at the maximum tolerated dose. Patients receive immunosuppression and will undergo active follow-up for two years, with longer-term safety monitoring for up to 15 years.

Grant Support Limits Annual Spending

HUNT1 had received $16 million in translational funding from the California Institute for Regenerative Medicine, according to Lineage’s acquisition announcement. A $12 million grant to UC Irvine funds the current trial.

Chief Financial Officer Jill Howe said Lineage estimates annual clinical costs below $2 million, including its obligation to contribute up to $3.1 million toward the grant. Management expects those costs to fit within its historical annual spending budget of approximately $30 million.

Lineage paid NeuroAirmid shareholders $2.4 million in cash and issued approximately 2.2 million common shares valued at $2.1 million. Cash payments to third parties added $1.9 million.

On the closing’s first anniversary, Lineage plans to pay shareholders up to approximately $2.6 million in cash and $2.4 million in shares, plus $356,000 in cash to the grant agency. Subsequent shareholder payments depend on clinical progress; Lineage can elect to pay half in stock.

Lineage had $45.2 million in cash, cash equivalents and marketable securities as of September 30, 2026. The acquisition puts another clinical program into that budget while shortening the period those funds are expected to cover.

The immediate manufacturing task is to qualify the newly filled bank. Existing trial supplies give Lineage room to develop its replacement process while the remaining patients enroll.

Sources

More on Lineage Cell Therapeutics

All Lineage Cell Therapeutics (LCTX) coverage →